Abstract
The recent research area endeavors to discover ultimate multi-target ligands, an increasingly feasible and attractive alternative to existing mono-targeted drugs for treatment of complex, multi-factorial inflammation process which underlays plethora of debilitated health conditions. In order to improvise this option, exploration of relevant chemical core scaffold will be an utmost need. Privileged benzimidazole scaffold being historically versatile structural motif could offer a viable starting point in the search for novel multi-target ligands against multi-factorial inflammation process since, when appropriately substituted, it can selectively modulate diverse receptors, pathways and enzymes associated with the pathogenesis of inflammation. Despite this remarkable capability, the multi-target capacity of the benzimidazole scaffold remains largely unexploited. With this in focus, the present review article attempts to provide synopsis of published research to exemplify the valuable use of benzimidazole nucleus and focus on their suitability as starting scaffold to develop multi-targeted anti-inflammatory ligands.
Keywords: Anti-inflammatory drug targets, inflammation, multi-factorial, multi-target ligand, privileged scaffold.
Mini-Reviews in Medicinal Chemistry
Title:Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-inflammatory Ligands
Volume: 14 Issue: 9
Author(s): Gaganpreet Kaur, Maninder Kaur and Om Silakari
Affiliation:
Keywords: Anti-inflammatory drug targets, inflammation, multi-factorial, multi-target ligand, privileged scaffold.
Abstract: The recent research area endeavors to discover ultimate multi-target ligands, an increasingly feasible and attractive alternative to existing mono-targeted drugs for treatment of complex, multi-factorial inflammation process which underlays plethora of debilitated health conditions. In order to improvise this option, exploration of relevant chemical core scaffold will be an utmost need. Privileged benzimidazole scaffold being historically versatile structural motif could offer a viable starting point in the search for novel multi-target ligands against multi-factorial inflammation process since, when appropriately substituted, it can selectively modulate diverse receptors, pathways and enzymes associated with the pathogenesis of inflammation. Despite this remarkable capability, the multi-target capacity of the benzimidazole scaffold remains largely unexploited. With this in focus, the present review article attempts to provide synopsis of published research to exemplify the valuable use of benzimidazole nucleus and focus on their suitability as starting scaffold to develop multi-targeted anti-inflammatory ligands.
Export Options
About this article
Cite this article as:
Kaur Gaganpreet, Kaur Maninder and Silakari Om, Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-inflammatory Ligands, Mini-Reviews in Medicinal Chemistry 2014; 14 (9) . https://dx.doi.org/10.2174/1389557514666140820120518
DOI https://dx.doi.org/10.2174/1389557514666140820120518 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dedication to Professor Tony Dodi
Current Cancer Therapy Reviews Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Adipokines, Metabolism and the Immune Response in the Regulation of Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets Recent Studies on Natural Products as Anticancer Agents
Current Topics in Medicinal Chemistry MicroRNAs - Key Players in Haematopoiesis
Current Signal Transduction Therapy Stem Cell Guardians – Old and New Perspectives in LSC Biology
Current Drug Targets Basis for Resistance to Imatinib in 16 BCR-ABL Mutants as Determined Using Molecular Dynamics
Recent Patents on Anti-Cancer Drug Discovery Inhibitors of ABL and the ABL-T315I Mutation
Current Topics in Medicinal Chemistry Vitamin D and Lung Cancer
Current Respiratory Medicine Reviews (1→3)-α-D-Glucans from Aspergillus spp.: Structural Characterization and Biological Study on their Carboxymethylated Derivatives
Current Drug Targets Humoral Immunity in HIV-1 Exposure: Cause or Effect of HIV Resistance?
Current HIV Research Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics
Current Pharmaceutical Biotechnology Hypocholesterolemia
Current Vascular Pharmacology Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Antiviral Immunotherapy for Mosquito-Borne Flaviviruses: A Review of Current Status
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Recent Patents on Nanotechnology The Molecular Basis of Notch Signaling Regulation: A Complex Simplicity
Current Molecular Medicine Doxycycline as Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Anticancer Activity of Some 2-[3/4-(2-Substituted Phenyl-2- oxoethoxy)benzylidene]-6-substituted-2,3-dihydro-1H-inden-1-one Derivatives
Letters in Drug Design & Discovery